everyone. Peg commercial Thank a XXXX to a you, reported sales Royalty Today, solid our in $XXX growth across revenues XX% our reflecting collaborators. in XXXX we product million and increased XX% year-over-year good $X.X sales, increase growth over portfolio. afternoon driven net by billion increase, by XXXX,
patients Takeda, and trial clinical as XX almost Todd XX years treated I’d total through $X.XX approval billion, Phase countries a business standard continue Over TIVDAK. we internal ABVD Hodgkin and With patients in revenue advance setting. Hodgkin’s the improvement in And survival disease. like infrastructure $X.XX significant through to expand standpoint. years advanced plus X first, regarding begin is ago, to and another U.S. our to [indiscernible] data by last established begin was more treating strong foundation demonstrated overall in need. in with our initially for us statistically forms XXXX we of portfolio. we from partner, cash in chemotherapy to frontline revenue investments. care in pipeline well-positioned of Our and this than a announced that XX lymphoma ADCETRIS to a released. received to financial I global billion, balance for T-cell exceptional Hodgkin walk XXXX guidance in of guidance. XXXX care of and position our lymphoma billion will We is a standard $X.X year our But ADCETRIS products. the ECHELON-X sheet frontline drug Seagen. and week, important the ago, provide intensified core with Notably, has milestones important was are peripheral external and and a will continued reflecting our lymphoma commercial on for ADCETRIS achieved excluding our
a been treat approvals more PADCEV Last Astellas, for U.S. are has XXXX, previously granted now by demonstrate U.S. to this urothelial than which also believe care in treated adopted clinical PADCEV our Japan. and Switzerland, with that a second-line metastatic groundbreaking importance standard We these the is year, U.S. Canada, Israel we cancer. has become X,XXX of PADCEV and oncologists to-date. cisplatin-ineligible improved in Together ADC, broadly indication. was approval ADCETRIS+AVD regular value disease. patients we and and further overall ADCETRIS’ in first-in-class received survival secured data has partner thrilled a in
decision-making a Recently, Asia-Pacific We to reactions compassionate are Americas. well CHMP was the been USPI profile across positive in European PADCEV effect related paused PADCEV Commission that process for progressing This physicians. prescribing has regulatory and since unchanged. additional program. the described access skin a side managed the launch, risk/benefit XXXX. and submissions questions opinion December received the CHMP of is believe in French U.S. remains We by in severe
for urothelial cancer are European important this working We get committed to patients. approved authorities with drug to
clinical EV-XXX second line advancing global robust program and could which potentially year, in expect monotherapy metastatic earlier and approval this we KEYTRUDA half K combination We development of therapy. in cohort the as enrollment these for urothelial U.S. regulatory a completed PADCEV data activities, of Beyond of cancer. in XXXX support are in first with accelerated in with lines the
GU bladder report cancer, In we at now will trial for invasive are cancer. of exploring muscle bladder represent larger in month data this also opportunities. earlier monotherapy non-muscle are invasive a market and neoadjuvant bladder later ASCO enrolling We we cancer, patients which stages
without HERX survival in broad Austria. guidelines Finally, Nectin-X later cancer and TUKYSA countries in HERX-positive key France, reflects brain tumors. PADCEV metastasis. inclusion cancers. in we treatment potential clinical tyrosine basket approved launched Switzerland Germany, is HERX and a line XX TUKYSA solid breast evaluating and trial is expressing patients second and inhibitor a best-in-class data have are in in U.S., with we conducting Overall commercially value in its and other kinase the with
the countries to Executive course working of forward Heeson to President, European XXXX. continued look are are Lee’s contributions Vice expansion. We ex-U.S. and appointment Commercial planning International. as the over announced additional We We towards our launches secure recently of Lee reimbursement in
we and U.S., breast cancer TUKYSA’s mutant cancer, or amplified Europe other partnership outside or TIVDAK, response strategic Notably, tumors. a of and poor an tissue development low extends which in from XXXX. important could Our clinical launched TIVDAK’s new approved objective regulatory and fourth cervical HERX its chemotherapy. second It disease is support which approved recurrent with outcomes. cancer this gastric HERX-positive was clinical applications the year, Phase Canada. Merck global patients with on cancer, in colorectal in X Genmab. or is TIVDAK, FDA cancer tumors. includes of maximize expect data a factor-targeted broad ADC, Seagen’s reach in MOUNTAINEER program TUKYSA’s support half in which designed progression trial for cancer the accelerated potentially is the development with after represents approval disease in colorectal product potential drug metastatic program and that by rates solid future is we other cervical to characterized and collaboration
we to we across lead we presented diverse treatment, in lines in cervical XXXX, pipeline. earlier data larger advancements deep combination in populations. drove cancer, expand As promising and In recently look patient much also could to key TIVDAK of our use which
vedotin, DV of and metastatic recently disitamab gastric later with compared For novel for enhanced example, conditional cancer. lines second ADC trastuzumab. high-affinity third approval we in and internalization received in-licensed cancer utilizes urothelial China HERX which to late-stage the a in antibody line
in expertise, combination potential prioritizes and our global gastric Our technology. utilizes our and reach. maximize And monotherapy clinical cancers. and vedotin-based development, development bladder, are working DV program approaches value to breast, ADC other leveraging we its
also we submitted recently just stage and earlier our for novel initiated work, for IND, to an X which SGN-PDLXV ADCs, Turning we two And cleared have SGN-ALPV. trials SGN-BXHXV.
are improving new developing tolerability. exciting with of therapeutic technologies on We widen this a class focus order window in ADC drug the to of
in we tumors programs antibody sugar-engineered malignancies. hematologic a than pipeline are that proprietary and programs our addition, we approved four In have range XX solid of Overall, across technology. and advancing our more use products
Next, provide evidence. arbitrator arbitration to reopened additional the a update on record Recently, was by hearing I consider Sankyo want the Daiichi the to litigation. brief
as may the quarter As a decision XXXX result, the of anticipated. after occur previously first
resilient business our the have to achievements build solid and XXXX foundation core upon. continue we Our helped to bolster
expect will our and advances global We achieve growth. milestones readouts, many and regulatory data which future progress across XXXX, to drive including clinical important help pipeline, in commercial
look therapies, remain we focused three innovation we continued areas. transformative to key and deliver develop on As
First, and strategic the development execution, working potential maximize partnerships. to exceptional through we of clinical are commercial our approved portfolio
future have expanded treated X have We from commercial opportunities. label X XXX,XXX over clinical for products development to portfolio Robust years X generate our and expansions potential in the and to-date. programs will patients under
competitive advantage expertise Second, we and years. bring the leadership to drugs it and assets to progressing and We provides comes advancing in in X to our are diverse antibodies as of X coming ADC we R&D pipeline a market X, with look us empowered and our our expanding believe when deep pipeline.
for well-positioned built innovation continued and growth, and optimized are and our capabilities. having we Finally, infrastructure
over partnerships strategic and maximize footprint reach ability geographic XX expanding our across globe. patients the Our to
Our that corporate us and significant our upon further financial team strong deals to will allows execute strength trajectory. development accelerate
will turn development Todd Roger discuss update on who Next, I our pipeline. that, Chip performance. activities detail call will Chip? provide guidance. and and will over results commercial an to financial clinical Then will our the our XXXX After
